TCGA-AN-A0FD-01A-11R-A034-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 7
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.550
- INTERFERON_ALPHA_RESPONSE+0.480
- INTERFERON_GAMMA_RESPONSE+0.370
- PANCREAS_BETA_CELLS+0.360
- HEDGEHOG_SIGNALING+0.350
- MYC_TARGETS_V2+0.350
- ANGIOGENESIS+0.230
- TGF_BETA_SIGNALING+0.220
- COAGULATION+0.190
- ALLOGRAFT_REJECTION+0.170
Top 10 suppressed
- E2F_TARGETS-0.210
- FATTY_ACID_METABOLISM-0.160
- ADIPOGENESIS-0.150
- CHOLESTEROL_HOMEOSTASIS-0.140
- OXIDATIVE_PHOSPHORYLATION-0.140
- PEROXISOME-0.140
- PROTEIN_SECRETION-0.120
- XENOBIOTIC_METABOLISM-0.120
- HEME_METABOLISM-0.110
- PI3K_AKT_MTOR_SIGNALING-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-B6-A0WY-01A-11R-A109-07 | — | A | 0.711 |
| 2 | TCGA-50-5044-01A-21R-1858-07 | — | cohortA1 | 0.703 |
| 3 | TCGA-FD-A43Y-01A-21R-A26T-07 | — | — | 0.688 |
| 4 | ERR2278864 | — | — | 0.686 |
| 5 | TCGA-CQ-A4C7-01A-11R-A24Z-07 | — | — | 0.684 |
| 6 | BSR_12_0194_A1_S68 | — | A | 0.666 |
| 7 | SRR5088832 | — | — | 0.650 |
| 8 | TCGA-CV-7235-01A-11R-2016-07 | — | — | 0.646 |
| 9 | TCGA-CQ-5330-01A-01R-1686-07 | — | — | 0.637 |
| 10 | TCGA-CV-A464-01A-11R-A266-07 | — | — | 0.635 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.550 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.480 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.370 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.360 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.350 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.350 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.230 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.220 | Inavolisib | — uncovered |
| COAGULATION | 0.190 | Binimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.170 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.170 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.160 | Inavolisib | — uncovered |
| MYOGENESIS | 0.160 | Inavolisib | — uncovered |
| HYPOXIA | 0.140 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.140 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |